Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kidney transplant patients: drug may prevent rejection with fewer side effects

NCT ID NCT05983770

Disease control Sponsor: Eledon Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study tested a new medicine called tegoprubart in 127 people who received a kidney transplant. The goal was to see if it works better than the standard drug tacrolimus at preventing the body from rejecting the new kidney. Participants took the study drug and were monitored for one year to check kidney function and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

127 people

The number who actually took part.

Started

Aug 2023

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female ≥ 18 years of age * Recipient of their first kidney transplant from a living or deceased donor * Agree to comply with contraception requirements during and for at least 90 days after the last administration of study drug Exclusion Criteria: * Induction therapy, other than study assigned rATG, planned as part of initial immunosuppressive regimen * Currently treated with any systemic immunosuppressive regimen, including immunologic biologic therapies * Currently treated with corticosteroids other than topical or inhaled corticosteroids * Will receive a kidney with an anticipated cold ischemia time of \> 30 hours * Will receive a kidney from a donor that meets any of the following: * 5a. Donation after Cardiac Death (DCD) criteria; Or * 5b. Kidney Donor Profile Index (KDPI) of \> 85%; Or * 5c. Is blood group (ABO) incompatible * Medical conditions that require chronic use of systemic corticosteroids or other immunosuppressants * History of a thromboembolic event, known hypercoagulable state, or condition requiring long term anticoagulation * Positive T- or B-cell crossmatch that is due to HLA antibodies or presence of a DSA at Screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure transplant rejection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney transplant rejection

Contacts and locations

Locations

  • Augusta University

    Augusta, Georgia, 30912, United States

  • CHRU Tours - Hopital Bretonneau

    Tours, France

  • CHU Grenoble-Alpes - Hopital Nord Michallon

    Grenoble, France

  • CHU de Toulouse - Hopital de Rangueil

    Toulouse, France

  • Centre Hospitalier Universitaire Dupuytren

    Limoges, 87042, France

  • Charite Universitatsmedizin Berlin

    Berlin, Germany

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Emory University Hospital

    Atlanta, Georgia, 30322, United States

  • Fiona Stanley Hospital

    Perth, Western Australia, 6150, Australia

  • Fundação Oswaldo Ramos - Hospital do Rim

    São Paulo, Brazil

  • Groupe Hospitalier Pellegrin

    Bordeaux, France

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Hospital Clinic de Barcelona

    Barcelona, 08036, Spain

  • Hospital Germans Trias i Pujol

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitari de Bellvitge

    Barcelona, Spain

  • Hospital das Clínicas da Faculdade de Medicina de São Paulo

    São Paulo, Brazil

  • Hospital del Mar - Parc de Salut Mar

    Barcelona, 08003, Spain

  • Johns Hopkins University

    Baltimore, Maryland, 21287, United States

  • Keck School of Medicine of USC

    Los Angeles, California, 90033, United States

  • Loyola University Medical Center

    Maywood, Illinois, 60153, United States

  • Massachusetts General Hospita;

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic

    Rochester, Minnesota, 55907, United States

  • Medstar Georgetown University Hospital

    Washington D.C., District of Columbia, 20007, United States

  • New York University Langone Health - Tisch Hospital

    New York, New York, 10016, United States

  • Royal Adelaide Hospital

    Adelaide, South Australia, 5000, Australia

  • St. Paul's Hospital

    Vancouver, British Columbia, Canada

  • Tampa General Hospital

    Tampa, Florida, 33606, United States

  • Tulane Medical Center

    New Orleans, Louisiana, 70112, United States

  • UT Southwestern

    Dallas, Texas, 75235, United States

  • University of California Los Angeles

    Los Angeles, California, 90024, United States

  • University of California, Davis Medical Center

    Sacramento, California, 95817, United States

  • University of California, Irvine Medical Center

    Orange, California, 92868, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Cincinnati Medical Center

    Cincinnati, Ohio, 45219, United States

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160, United States

  • University of Minnesota Medical Center

    Minneapolis, Minnesota, 55455, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198, United States

  • University of Pittsburgh Medical Center

    Harrisburg, Pennsylvania, 17104, United States

  • University of Washington Medical Center

    Seattle, Washington, 98195, United States

  • University of Wisconsin Health

    Madison, Wisconsin, 53792, United States

  • Virginia Commonwealth University

    Richmond, Virginia, 23298, United States

  • Washington University in St. Louis

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.